Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Foreign Exchange Impact on Sales Growth (%) (%)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, FY2023
-0.2%
Period ended Dec 31, 2023
Change on a year earlier
–
History
1 years
Since FY2023
Sources
1
SEC Filing (0001628280-24-002009)
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Foreign Exchange Impact on Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | -0.2% | – | SEC Filing (0001628280-24-002009) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Foreign Exchange Impact on Sales Growth (%) (%), annual FY2023–FY2023 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-poc-leg-fx
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.